⌕
Veracyte · VCYT · Nasdaq
Tenet 78 · Strong
Compare
$24.01−1.32%At closeTenet 78 · Strong
$24.01−0.32 (−1.32%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Veracyte (VCYT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~23.9%/yr (FY21→FY25), net margin 12.8%, and free cash flow (~$126.6M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+18.7%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲16.0%
517.1
FY21→FY25CAGR +23.9%/yr
Net income ($M)▲174.9%
66.4
FY21→FY25CAGR —
Free cash flow ($M)▲98.5%
126.6
FY21→FY25CAGR —
Diluted EPS▲164.5%
0.82
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+18.7%

67.9mn → 80.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$9.7M

steady at 1.9% of revenue (−14.3% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)517.1Revenue−154.6COGS362.5Gross profit−70.8R&D−110.8SG&A57.8Op income8.6Tax & other66.4Net income

13¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~4%FY21FY25

Over this window: gross 66.1% → 70.1%. Net margin 12.8% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
581,782.0517,145.0445,764.0361,051.0296,536.0219,514.0▲16.0%+23.9%
Cost of revenue
162,439.0154,613.0147,619.0131,367.0120,855.074,400.0▲4.7%+20.1%
Gross profit
418,785.0362,532.0298,145.0229,684.0175,681.0145,114.0▲21.6%+25.7%
Research & development
109,548.070,814.069,294.057,305.040,603.029,843.0▲2.2%+24.1%
Selling, general & admin
97,792.0110,784.0110,610.086,229.073,200.0101,353.0▲0.2%+2.2%
Total operating expenses
330,815.0315,421.0293,555.0333,943.0236,035.0227,017.0▲7.4%+8.6%
Operating incomefeeds ROC rank
99,390.057,777.016,142.0−85,795.0−41,081.0−81,903.0▲257.9%—
Other income, net
18,863.010,424.09,602.09,183.04,654.0254.0——
Pretax income
118,253.068,201.025,744.0−76,612.0−36,427.0−81,649.0▲164.9%—
Income tax
−8,596.01,848.01,606.0−2,208.0133.0−6,086.0▲15.1%+140.4% (22→25)
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
126,849.066,353.024,138.0−74,404.0−36,560.0−75,563.0▲174.9%—
Per share
Diluted EPSbuyback-sensitive
1.540.820.31−1.02−0.51−1.11▲164.5%—
Diluted shares (mn)
82.7880.5778.1672.6471.5567.89▲3.1%+4.4%
Margins
Gross margin61st pct in Healthcare
72.0%70.1%66.9%63.6%59.2%66.1%▲3.2pp+4.0pp
Operating margin
17.1%11.2%3.6%−23.8%−13.9%−37.3%▲7.6pp+48.5pp
Net margin88th pct in Healthcare
21.8%12.8%5.4%−20.6%−12.3%−34.4%▲7.4pp+47.3pp
† TTM = trailing four quarters through 2026-09-30.
FY11 – FY20 · 10 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Veracyte's revenue last fiscal year?

Veracyte reported revenue of $517.1M in fiscal 2025, up 16.0% from fiscal 2024.

What was Veracyte's net income?

Veracyte reported net income of $66.4M in fiscal 2025, a net margin of 12.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.